Price movement over the last 24 hours
Alcon AG vs Trade Desk Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Trade Desk Inc trades at $19.04 (market cap $9.02B). The key difference: Alcon AG is far larger — about 3.6× Trade Desk Inc's market cap, and Alcon AG pays a 0.54% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| ALC | TTD | |
|---|---|---|
Market Cap | $32.69B | $9.02B |
Sector | Health | Technology |
52-Week High | $92.22 | $89.76 |
52-Week Low | $62.02 | $17.33 |
Enterprise Value | $36.28B | $8.03B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
The Trade Desk (TTD) trades at $19.18, up 0.42% with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company maintains strong profitability with 77.83% gross margins and 14.57% net income margin, though Q1 2026 earnings missed expectations. Revenue growth has been consistent, reaching $2.9B in 2025, while analyst sentiment remains divided with a $25.46 consensus target representing 33% upside potential.
TTD presents a compelling value opportunity with reasonable valuations (P/E 21.94, P/S 3.17) and strong cash flow generation, but faces near-term headwinds from recent earnings miss and competitive pressures in digital advertising. The stock's 86% decline from 2024 highs creates potential for recovery if execution improves, though investor caution is warranted given mixed analyst ratings and technical weakness.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →